ArticleUltrasonography (Seoul, Korea)2026
Direct comparison of ultrasound-guided attenuation parameter and controlled attenuation parameter for steatosis using MRI-based proton density fat fraction as a reference.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatic steatosis, which is associated with liver diseases and adverse clinical outcomes, requires accurate, noninvasive diagnostic methods because of the limitations of liver biopsy. This study aimed to evaluate the effectiveness of the ultrasound-guided attenuation parameter (UGAP), a novel technique for assessing hepatic steatosis, and to compare its diagnostic performance with that of the controlled attenuation parameter (CAP), using magnetic resonance imaging (MRI)-derived proton density fat fraction (PDFF) as the reference standard.
methodsA total of 255 patients with chronic liver disease who underwent CAP, UGAP, and MRI-PDFF were prospectively enrolled from three liver centers in Japan. Using the area under the receiver operating characteristic curve (AUROC) analysis, cutoff values for UGAP were determined according to steatosis grades based on MRI-PDFF. To minimize overfitting, diagnostic performance was validated using five-fold cross-validation.
resultsCAP and UGAP values followed normal distributions, whereas PDFF values deviated from normality and were therefore log-transformed, yielding the variable MRI-logPDFF. CAP and UGAP demonstrated significant correlations with MRI-logPDFF, with intraclass correlation coefficients of 0.696 and 0.797, respectively. For MRI-PDFF-based grading, the AUROC (95% confidence interval) values of CAP and UGAP were 0.878 (0.813-0.923) versus 0.926 (0.867-0.960) for S0 versus S1-S3 (P=0.041), 0.820 (0.763-0.865) versus 0.908 (0.861-0.940) for S0-S1 versus S2-S3 (P<0.001), and 0.863 (0.811-0.902) versus 0.897 (0.852-0.930) for S0-S2 versus S3 (P=0.128), respectively. The validation analysis produced results consistent with those of the primary cohort.
conclusionUGAP showed greater diagnostic accuracy than CAP for hepatic steatosis, notably in detecting grades ≥S1 and ≥S2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.